ERYTECH to Host First Quarter 2018 Conference Call and Business Update
ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call and webcast on Tuesday, May 15, 2018, at 2:30 PM CEST/8:30 AM EST to discuss operational highlights.
The call is accessible via the below teleconferencing numbers, followed by the Conference ID#: 3498017#:
USA/Canada: +1 409 350 3501
United-Kingdom: +44 2031070289
Switzerland: +41 445802606
Germany: +49 6922224728
France: +33 176748988
Belgium: +32 24003547
Sweden: +46 856619361
Finland: +358 972519310
Netherlands: +31 207075547
Spain: +34 914142503
The webcast can be followed live online via the link: https://edge.media-server.com/m6/p/wq3dzxoy .
An archived replay of the call will be available for 7 days by dialing + 1 800 585 8367, Conference ID: 3498017#. An archive of the webcast will be available on ERYTECH’s website, under the “Investors” section at http://investors.erytech.com .
About ERYTECH and eryaspase (GRASPA®): www.erytech.com
Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.
The Company’s lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.
Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.
ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.
In addition to eryaspase, ERYTECH is developing erymethionase, methionine-γ-lyase encapsulated in red blood cells, to target cancer cells’ amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
Director of Investor Relations
+33 4 78 74 44 38
+1 917 312 5151
+33 1 44 71 98 52 firstname.lastname@example.org
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
IDEMIA20.2.2019 14:30:02 | Pressemeddelelse
IDEMIA Changes Its Management Structure to Consolidate Its Augmented Identity Global Leadership and Appoints Pierre Barrial CEO of Its New Secure Enterprise Transactions Division
CA-HSH20.2.2019 14:02:07 | Pressemeddelelse
The Peninsula Hotels Named First and Only Hotel Brand to Achieve Forbes Travel Guide Five-Star Status across Entire Portfolio
WA-OPANGA-NETWORKS20.2.2019 14:02:06 | Pressemeddelelse
Opanga Networks Announces Next Generation of Network Densification Machine Learning Software
HCL-TECHNOLOGIES20.2.2019 12:53:10 | Pressemeddelelse
EDF Luminus Selects HCL to Drive Digital Transformation Through Cloud Migration
HENLEY-&-PARTNERS20.2.2019 12:51:10 | Pressemeddelelse
Global Strategist Dr. Parag Khanna joins Henley & Partners’ Board of Advisors
SIGFOX20.2.2019 11:02:08 | Pressemeddelelse
Sigfox 0G Network on Track to Establishing a Standard
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum